Literature DB >> 31974753

CO2 Laser Moxibustion for Knee Osteoarthritis: Study Protocol for A Multicenter, Double-blind, Randomized Controlled Trial.

Meng-Hu Guo1, Ling Zhao1, Fan Wu1, Jiong Du2, Chen-Huan Ding3, Jing-Hua Ge4, Ming T Tan5, Li-Xing Lao6, Xue-Yong Shen1, Ke Cheng7.   

Abstract

BACKGROUND: Knee osteoarthritis (OA) is a major cause of disability among the older adults. Few treatments are safe and effective. Moxibustion is commonly used in treating knee OA in Chinese medicine (CM). CO2 Laser moxibustion device is a substitute for traditional moxibustion, which mimics the effects of traditional moxibustion. More data are needed to support its application in knee OA.
OBJECTIVE: ObjectiveThe trial aims to assess the effect and safety of CO2 laser moxibustion in patients with knee osteoarthritis compared with a sham control.
METHODS: This is a protocol for a multicenter, randomized, double-blind, placebo-controlled trial. A total of 392 participants were recruited and assigned to the CO2 laser moxibustion group and sham laser moxibustion group with a 1:1 ratio at 6 outpatient clinics in Shanghai, China. Participants in both groups received treatment at the affected knee(s) at the acupuncture point Dubi (ST 35) and an Ashi point. There were 3 sessions per week for 4 weeks, and an additional 20-week follow-up. Primary outcomes were changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores at week 4. Secondary outcomes were WOMAC function score, stiffness score and overall score, VAS pain, Short-Form heath survey (SF-36), and patients' global assessment. The serum levels of cytokines involved in progress of knee OA were explored. Safety was assessed during the whole trial. Masking effectiveness was assessed by both participants and treatment providers.This is a protocol for a multicenter, randomized, double-blind, placebo-controlled trial. A total of 392 participants were recruited and assigned to the CO2 laser moxibustion group and sham laser moxibustion group with a 1:1 ratio at 6 outpatient clinics in Shanghai, China. Participants in both groups received treatment at the affected knee(s) at the acupuncture point Dubi (ST 35) and an Ashi point. There were 3 sessions per week for 4 weeks, and an additional 20-week follow-up. Primary outcomes were changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores at week 4. Secondary outcomes were WOMAC function score, stiffness score and overall score, VAS pain, Short-Form heath survey (SF-36), and patients' global assessment. The serum levels of cytokines involved in progress of knee OA were explored. Safety was assessed during the whole trial. Masking effectiveness was assessed by both participants and treatment providers. DISCUSSION: CO2 laser moxibustion device, designed as a substitute for CM moxibustion, is easy to use and control with no choking smoke and smell, and is a plausible method for double-blind research. This study would provide rigorous evidence for the effect and safety of CO2 laser moxibustion in treating knee OA (Trial registration No.: ISRCTN15030019).

Entities:  

Keywords:  Chinese medicine; knee osteoarthritis; laser moxibustion; pain; randomized controlled trial

Mesh:

Substances:

Year:  2020        PMID: 31974753     DOI: 10.1007/s11655-019-2714-6

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  3 in total

Review 1.  Research Trends of Moxibustion Therapy for Pain Treatment Over the Past Decade: A Bibliometric Analysis.

Authors:  Yunfan Xia; Ruohan Sun; Rongrong Li; Leilei Ren; Yiyi Wang; Jianqiao Fang
Journal:  J Pain Res       Date:  2022-08-20       Impact factor: 2.832

2.  Ultrasonic device developed for non-invasive moxibustion therapy.

Authors:  Geonwoo Kim; Young-In Hwang; Yeonhee Ryu; Hak-Joon Kim; Young-Min Bae; Ki-Bok Kim
Journal:  Integr Med Res       Date:  2021-05-19

3.  10.6-μm infrared laser as adjuvant therapy for diabetic peripheral neuropathy: study protocol for a double-blind, randomized controlled trial.

Authors:  Lin Lin; Yi Chen; Yuxia Li; Ke Cheng; Haiping Deng; Jianping Lu; Ling Zhao; Xueyong Shen
Journal:  Trials       Date:  2022-01-18       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.